QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
28 Setembro 2023 - 5:05PM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today
the expansion of its clinical decision support software, QIAGEN
Clinical Insight Interpret (QCI Interpret), to include artificial
intelligence (AI)-enhanced coverage of thousands of rare disease
genes, advancing its AI-capabilities that have been established for
over two decades. The expansion complements the human-certified
content curation of QCI Interpret and enables complete
bibliographical coverage of the clinical exome.
New features include:
- Additional AI-derived literature references for thousands of
additional genes in the clinical genome to supplement
QIAGEN-curated content. The unique combination of human-certified
and AI-derived content not only saves considerable time in the
prioritization, assessment, and interpretation of clinically
relevant variants but ensures diagnostic labs have access to
complete and trusted evidence as they onboard and deploy larger
gene panels.
- Enhancement of the AI-trained phenotype-driven ranking. This
advanced feature significantly increases the diagnostic power of
exome sequencing by improving the accuracy and efficiency of
identifying disease-gene associations. In addition, QCI Interpret
users can now filter publications to focus exclusively on
phenotype-related references. With one click, they can pull only
publications relevant to the patient's genome and phenotype,
significantly reducing time spent reviewing the literature for each
variant classification.
- Advancement for somatic NGS testing with QCI Interpret for
Oncology, providing new report revisioning capabilities,
streamlined filtering of structural variants, and quick
identification of disease-relevant clinical literature
“As costs for whole-genome and whole-exome
sequencing decrease, clinical labs face bottlenecks in NGS
interpretation,” said Jonathan Sheldon, Senior Vice President of
QIAGEN Digital Insights. “We help researchers to overcome this
challenge by broadening the content of QCI Interpret, now covering
the whole exome thanks to additional AI capabilities. By bringing
human-curated and AI-derived content together, we deliver complete,
trusted and accurate evidence to our customers and offer them the
highest quality and most comprehensive clinical NGS reporting
solution on the market.”
For over two decades, QCI Interpret has combined
the accuracy and consistency of QIAGEN’s proprietary expert
(MD/PhD) curation with the superior efficiency of machine curation
(AI-powered) to enable high-confidence variant interpretation and
reporting. With over 3.5 million NGS patient test cases analyzed
and interpreted worldwide, QCI Interpret is one of the most widely
used and universally respected platforms for efficiently accessing
clinical evidence to support confident decision-making in genetic
testing.
QCI Interpret continuously expands its global
footprint and is adopted by an increasing number of programs and
institutions. For example earlier this year, the Danish National
Genome Center selected QCI Interpret for variant interpretation in
oncology genome sequencing. The software will be used at testing
sites throughout Denmark and support the nationwide initiative to
offer sequencing-based solutions for cancer patients.
Learn more about the latest release of QCI
Interpret here:
https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/qiagen-clinical-insight/qci-interpret/
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
June 30, 2023, QIAGEN employed more than 6,100 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024